User login
Key clinical point: Patients with early rheumatoid arthritis (RA) had a higher frequency of adverse events (AE) with methotrexate + tociluzumab vs methotrexate + active conventional treatment (ACT), which restricted their ability to tolerate the target dose of 25 mg methotrexate per week.
Major finding: The risk for methotrexate-associated AE was significantly higher (hazard ratio 1.48; 95% CI 1.20-1.84) and the proportion of patients able to tolerate 25 mg methotrexate per week at 24 weeks was significantly lower (odds ratio 0.25; P < .001) in the methotrexate + tocilizumab vs methotrexate + ACT group. However, the risks for methotrexate-associated AE were comparable for methotrexate +ACT and the combinations of methotrexate with other biologics like certolizumab-pegol or abatacept.
Study details: This post hoc analysis of the phase 4 NORD-STAR trial included 812 treatment-naive patients with early RA who were randomly assigned to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab.
Disclosures: This study did not receive any specific funding. Some authors declared receiving grants, contracts, payments, honoraria, or consulting fees from or having other ties with various sources.
Source: Lend K et al. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: A post-hoc analysis of a randomized controlled trial (NORD-STAR). Arthritis Rheumatol. 2023 (Oct 17). doi: 10.1002/art.42730
Key clinical point: Patients with early rheumatoid arthritis (RA) had a higher frequency of adverse events (AE) with methotrexate + tociluzumab vs methotrexate + active conventional treatment (ACT), which restricted their ability to tolerate the target dose of 25 mg methotrexate per week.
Major finding: The risk for methotrexate-associated AE was significantly higher (hazard ratio 1.48; 95% CI 1.20-1.84) and the proportion of patients able to tolerate 25 mg methotrexate per week at 24 weeks was significantly lower (odds ratio 0.25; P < .001) in the methotrexate + tocilizumab vs methotrexate + ACT group. However, the risks for methotrexate-associated AE were comparable for methotrexate +ACT and the combinations of methotrexate with other biologics like certolizumab-pegol or abatacept.
Study details: This post hoc analysis of the phase 4 NORD-STAR trial included 812 treatment-naive patients with early RA who were randomly assigned to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab.
Disclosures: This study did not receive any specific funding. Some authors declared receiving grants, contracts, payments, honoraria, or consulting fees from or having other ties with various sources.
Source: Lend K et al. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: A post-hoc analysis of a randomized controlled trial (NORD-STAR). Arthritis Rheumatol. 2023 (Oct 17). doi: 10.1002/art.42730
Key clinical point: Patients with early rheumatoid arthritis (RA) had a higher frequency of adverse events (AE) with methotrexate + tociluzumab vs methotrexate + active conventional treatment (ACT), which restricted their ability to tolerate the target dose of 25 mg methotrexate per week.
Major finding: The risk for methotrexate-associated AE was significantly higher (hazard ratio 1.48; 95% CI 1.20-1.84) and the proportion of patients able to tolerate 25 mg methotrexate per week at 24 weeks was significantly lower (odds ratio 0.25; P < .001) in the methotrexate + tocilizumab vs methotrexate + ACT group. However, the risks for methotrexate-associated AE were comparable for methotrexate +ACT and the combinations of methotrexate with other biologics like certolizumab-pegol or abatacept.
Study details: This post hoc analysis of the phase 4 NORD-STAR trial included 812 treatment-naive patients with early RA who were randomly assigned to receive methotrexate in combination with ACT, certolizumab-pegol, abatacept, or tocilizumab.
Disclosures: This study did not receive any specific funding. Some authors declared receiving grants, contracts, payments, honoraria, or consulting fees from or having other ties with various sources.
Source: Lend K et al. Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis: A post-hoc analysis of a randomized controlled trial (NORD-STAR). Arthritis Rheumatol. 2023 (Oct 17). doi: 10.1002/art.42730